

The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

JUNE 18, 2020

VOL. 382 NO. 25

Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults

F.-X. Blanc, A.D. Badje, M. Bonnet, D. Gabillard, E. Messou, C. Muzoora, S. Samreth, B.D. Nguyen, L. Borand, A. Domergue, D. Rapoud, N. Natukunda, S. Thai, S. Juchet, S.P. Eholié, S.D. Lawn,* S.K. Domoua, X. Anglaret, and D. Laureillard, for the STATIS ANRS 12290 Trial Team†

ABSTRACT

BACKGROUND

In regions with high burdens of tuberculosis and human immunodeficiency virus (HIV), many HIV-infected adults begin antiretroviral therapy (ART) when they are already severely immunocompromised. Mortality after ART initiation is high in these patients, and tuberculosis and invasive bacterial diseases are common causes of death.

METHODS

We conducted a 48-week trial of empirical treatment for tuberculosis as compared with treatment guided by testing in HIV-infected adults who had not previously received ART and had CD4+ T-cell counts below 100 cells per cubic millimeter. Patients recruited in Ivory Coast, Uganda, Cambodia, and Vietnam were randomly assigned in a 1:1 ratio to undergo screening (Xpert MTB/RIF test, urinary lipoarabinomannan test, and chest radiography) to determine whether treatment for tuberculosis should be started or to receive systematic empirical treatment with rifampin, isoniazid, ethambutol, and pyrazinamide daily for 2 months, followed by rifampin and isoniazid daily for 4 months. The primary end point was a composite of death from any cause or invasive bacterial disease within 24 weeks (primary analysis) or within 48 weeks after randomization.

RESULTS

A total of 522 patients in the systematic-treatment group and 525 in the guided-treatment group were included in the analyses. At week 24, the rate of death from any cause or invasive bacterial disease (calculated as the number of first events per 100 patient-years) was 19.4 with systematic treatment and 20.3 with guided treatment (adjusted hazard ratio, 0.95; 95% confidence interval [CI], 0.63 to 1.44). At week 48, the corresponding rates were 12.8 and 13.3 (adjusted hazard ratio, 0.97 [95% CI, 0.67 to 1.40]). At week 24, the probability of tuberculosis was lower with systematic treatment than with guided treatment (3.0% vs. 17.9%; adjusted hazard ratio, 0.15; 95% CI, 0.09 to 0.26), but the probability of grade 3 or 4 drug-related adverse events was higher with systematic treatment (17.4% vs. 7.2%; adjusted hazard ratio 2.57; 95% CI, 1.75 to 3.78). Serious adverse events were more common with systematic treatment.

CONCLUSIONS

Among severely immunosuppressed adults with HIV infection who had not previously received ART, systematic treatment for tuberculosis was not superior to test-guided treatment in reducing the rate of death or invasive bacterial disease over 24 or 48 weeks and was associated with more grade 3 or 4 adverse events. (Funded by the Agence Nationale de Recherches sur le Sida et les Hépatites Virales; STATIS ANRS 12290 ClinicalTrials.gov number, NCT02057796.)

The authors' full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr. Blanc at Service de Pneumologie, Hôpital G. et R. Laënnec, Centre Hospitalier Universitaire de Nantes, Blvd. J. Monod, F-44093 Nantes CEDEX 1, France, or at xavier.blanc@chu-nantes.fr.

*Deceased.

†A list of investigators and members of the STATIS ANRS 12290 Trial Team is provided in the Supplementary Appendix, available at NEJM.org.

Drs. Anglaret and Laureillard contributed equally to this article.

N Engl J Med 2020;382:2397-410.

DOI: 10.1056/NEJMoa1910708

Copyright © 2020 Massachusetts Medical Society.

TUBERCULOSIS IS THE 10TH LEADING cause of death worldwide and the main cause of death from a single infectious agent.¹ In 2019, the World Health Organization (WHO) estimated that 251,000 annual deaths due to tuberculosis occurred in persons with human immunodeficiency virus (HIV) infection.¹ Coinfection with tuberculosis and HIV still represents a “cursed duet,”² especially in sub-Saharan Africa and Asia.^{3,4} The WHO recommends that people living with HIV infection should be systematically screened for active tuberculosis and that those who report current cough, fever, weight loss, or night sweats should be evaluated for tuberculosis and other diseases.^{5,6} However, because of variations in the appearance of chest radiographs and the decrease in the performance of sputum-smear microscopy as the CD4+ T-cell count declines,⁷ a diagnosis of tuberculosis remains challenging in HIV-infected adults, especially when they are severely immunosuppressed.

Despite increasing access to antiretroviral therapy (ART) in regions with high burdens of tuberculosis and HIV, many HIV-infected adults still present for care when they are already severely immunocompromised.^{8,9} Among these adults, mortality after the initiation of ART is high, and tuberculosis and invasive bacterial diseases are common causes of death.¹⁰⁻¹⁷ Persons with active tuberculosis may report no or few symptoms. The use of the urinary lipoarabinomannan (LAM) test and Xpert MTB/RIF test (a rapid nucleic acid amplification test to detect *Mycobacterium tuberculosis* and resistance to rifampin) increases the chance of correctly diagnosing tuberculosis.¹⁸ However, physicians commonly initiate empirical treatment for tuberculosis without using these tests.^{19,20} One potential benefit of empirical treatment for tuberculosis is that rifampin is active against several common pathogens that can be fatal in patients with advanced HIV infection. We conducted a randomized, clinical trial to compare the benefits and risks of a tuberculosis-screening strategy involving a combination of investigations (urinary LAM test, Xpert MTB/RIF test, and chest radiography) and targeted treatment with those of a strategy of systematic empirical treatment for tuberculosis in HIV-infected patients with severe immunosuppression.

METHODS

TRIAL DESIGN AND OVERSIGHT

This research was sponsored and funded by the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS). The funding agency had no role in the trial design, the collection and analysis of the data, or the decision to submit the manuscript for publication. The STATIS (Systematic vs. Test-Guided Antituberculosis Treatment Impact in Severely Immuno-suppressed HIV-Infected Adults Initiating Antiretroviral Therapy with CD4 Cell Counts <100/mm³) ANRS 12290 trial was a multicenter, randomized, open-label, superiority trial that compared the efficacy of two strategies in reducing mortality and the risk of invasive bacterial diseases among ambulatory HIV-infected adults with no overt evidence of tuberculosis, whose CD4+ T-cell count was less than 100 cells per cubic millimeter, and who were ready to start ART (see Section 1.2 in the Supplementary Appendix, available with the full text of this article at NEJM.org). Patients were recruited between September 29, 2014, and May 3, 2017, in Abidjan, Ivory Coast (two centers); Mbarara, Uganda (two centers); Phnom Penh, Cambodia (one center); and Ho Chi Minh City, Vietnam (one center).

After written informed consent was obtained, the patients were randomly assigned in a 1:1 ratio to undergo screening to guide treatment for tuberculosis (guided-treatment group) or to receive systematic empirical treatment for tuberculosis (systematic-treatment group). A sequentially numbered block-randomization list was computer-generated and included in a software tool that allowed access to the next available trial identification number and treatment group. Randomization was stratified according to country (Ivory Coast, Uganda, Cambodia, or Vietnam) and baseline CD4+ T-cell count (≤ 50 cells per cubic millimeter or 51 to 99 cells per cubic millimeter). The trial was conducted in compliance with current international regulations, including the Declaration of Helsinki²¹ and the Good Clinical Practice guidelines from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use,²² and was approved by ethics and regulatory authorities in each country. The authors vouch for the accuracy and completeness

of the data and for the fidelity of the trial to the protocol, available at NEJM.org.

TRIAL INTERVENTIONS

The patients were evaluated by on-site physicians on the day of enrollment and randomization (day 0) and then at weeks 2, 4, 8, 12, 16, 20, 24, 36, and 48. Between these visits, the patients were asked to come to the clinic if they had any symptoms or concerns about treatment. On day 0, the patients assigned to the guided-treatment group underwent systematic tuberculosis screening by means of the Xpert MTB/RIF test, the Alere Determine TB LAM Ag urinary test, and chest radiography, regardless of reported symptoms. Only the patients who met the criteria for confirmed or probable tuberculosis, as determined by these tests, started treatment for tuberculosis in this group (see Section 1.4.4 in the Supplementary Appendix). The patients assigned to the systematic-treatment group underwent chest radiography but no other tuberculosis test, even if they reported tuberculosis symptoms; all the patients in this group started treatment for tuberculosis immediately.

During follow-up, the patients in the guided-treatment group who had not received treatment for tuberculosis were systematically screened for tuberculosis symptoms with the use of the 2010 WHO questionnaire⁵ at each visit. Those who answered “yes” to any of the four questions or who had any other clinical manifestations suggestive of tuberculosis underwent repeated screening with the Xpert MTB/RIF test, the urinary LAM test, and chest radiography, as well as any other appropriate symptom-driven investigation. Treatment for tuberculosis was initiated in the case of confirmed, probable, or possible tuberculosis. In the systematic-treatment group, patients whose condition had deteriorated before week 24 underwent symptom-driven investigations, including tuberculosis tests when immune reconstitution inflammatory syndrome (IRIS), drug resistance, or poor adherence was suspected. After week 24, the patients in the systematic-treatment group were screened for tuberculosis with the use of the same procedures that were used in the guided-treatment group.

In both groups, treatment for tuberculosis consisted of a daily oral regimen of isoniazid,

rifampin, ethambutol, and pyrazinamide in doses recommended by the WHO, as summarized in the protocol, for 2 months, followed by daily administration of isoniazid and rifampin for 4 months. All the patients received counseling regarding adherence and were offered prophylaxis with trimethoprim–sulfamethoxazole. ART consisted of efavirenz, plus lamivudine or emtricitabine, plus tenofovir or zidovudine, in accordance with the national guidelines from each country. In the guided-treatment group, ART was initiated immediately after randomization in the patients who did not receive a diagnosis of tuberculosis and 2 weeks later in the patients who did. In the systematic-treatment group, all the patients started ART 2 weeks after randomization.

TRIAL END POINTS

The primary end point was a composite of death from any cause or invasive bacterial disease within 24 weeks (primary analysis) or within 48 weeks (secondary analysis) after randomization. Invasive bacterial disease was defined as a bacteremia or clinical, biologic, or radiologic signs compatible with a bacterial infection of any solid organ or sterile space (standardized definitions of probable and confirmed invasive bacterial diseases are provided in Section 1.4.4.2 in the Supplementary Appendix). Secondary end points included death from any cause; serious adverse events (defined as invasive bacterial diseases, incident tuberculosis, other acquired immunodeficiency syndrome [AIDS]–defining diseases, and other grade 3 or 4 adverse events, as classified according to the Division of AIDS²³; IRIS²⁴; HIV-1 virologic suppression success (defined as a viral load of <50 copies per milliliter); change in CD4+ T-cell count from baseline; and adherence to treatment. These end points were classified according to standardized criteria (see Section 1.4 in the Supplementary Appendix) and were assessed at 24 and 48 weeks.

Adherence to ART was assessed by calculating the medication possession ratio (the number of daily doses of antiretroviral drugs dispensed by the pharmacy to each patient, divided by that patient’s total follow-up time in days since the initiation of ART). Adherence to antituberculous drugs was assessed according to the patient’s recall of the number of pills missed over the previ-

ous 4 days. All primary and secondary clinical end points were reviewed by two event-documentation committees, one at the trial center level and one at the international level. Members of the committees were aware of the treatment-group assignments.

STATISTICAL ANALYSIS

We estimated that the risk of death or invasive bacterial disease in the guided-treatment group would be 14% at 24 weeks.⁴ A sample size of 1050 patients was estimated to provide the trial with 80% power to show a 40% lower risk of death or invasive bacterial disease in the systematic-treatment group than in the guided-treatment group, with a two-sided type I error rate of 5% and a 4.5% loss to follow-up.

The main analyses of the primary and secondary end points were performed at week 24 on an intention-to-treat basis. The same analyses were performed at week 48 (end of the trial). We used the Kaplan–Meier method to estimate the cumulative probability of the occurrence of an event. Follow-up data were censored when patients were lost to follow-up. Multivariate Cox proportional-hazards models were used to compare the treatment groups with respect to event rates, with adjustment for country and baseline CD4+ T-cell count category. The proportional-hazards assumption was examined. All the patients who underwent randomization were included in the analysis, including the patients who died, were lost to follow-up, or withdrew from the trial. Patients who did not attend the last scheduled visit at 48 weeks, who were not known to have died, and who could not be found after intensive tracing were considered lost to follow-up. There was no imputation for missing data. Because the 95% confidence intervals of the between-group differences with respect to the secondary end points have not been adjusted for multiple comparisons, inferences cannot be made from the results.

RESULTS

CHARACTERISTICS OF THE PATIENTS

A total of 1050 patients were randomly assigned to a treatment group. Three patients were excluded from the analysis because they had previously received ART (Fig. 1). Data were obtained

from 525 patients in the guided-treatment group and 522 patients in the systematic-treatment group (Table 1). The median age of the patients was 35 years (interquartile range, 29 to 41), 436 (41.6%) were women, and the median CD4+ T-cell count was 30 cells per cubic millimeter (interquartile range, 12 to 56). At the time of enrollment, 94.7% of the patients had a Karnofsky performance-status score of at least 80 (on a scale from 0 to 100, with lower scores indicating greater disability), and 354 patients (67.4%) in the guided-treatment group and 346 (66.3%) in the systematic-treatment group reported no symptoms or one tuberculosis symptom. A total of 886 patient-years of follow-up (444 in the guided-treatment group and 442 in the systematic-treatment group) were completed. At trial termination, 24 patients (2.3%) were lost to follow-up (11 patients in the guided-treatment group and 13 patients in the systematic-treatment group). The percentage of patients who attended the scheduled trial visits through week 24 was 96.7%, and 95.3% attended the scheduled trial visits through week 48; the percentages in the two treatment groups did not differ meaningfully (Table S1 in the Supplementary Appendix). A total of 521 of 522 patients (99.8%) in the systematic-treatment group started treatment for tuberculosis, of whom 497 (95.4%) completed the 6-month treatment period (Table 1). In this group, the percentage of patients who reported having missed at least one antituberculous pill during the 4 days preceding a trial visit varied between 1% and 2% during follow-up (Fig. S4).

CLINICAL END POINTS

During follow-up, 90 patients died (69 before week 24) (Tables S16 and S17), and 42 cases of invasive bacterial disease occurred in 41 patients (34 cases occurred in 33 patients before week 24) (Table S18). The cases of invasive bacterial disease included 13 cases of bacteremia, 12 cases of pneumonia, 6 cases of severe sepsis, 5 cases of pyelonephritis, 2 cases of necrotizing fasciitis, 1 case of salpingitis, 1 cases of skin abscess, 1 case of bacterial enteritis, and 1 case of appendicitis. The proportional-hazards assumption was fulfilled. With respect to the primary outcome, the rate of death from any cause or invasive bacterial disease (calculated as the number of first




Figure 1. Screening, Randomization, and Follow-up.

The patients assigned to the guided-treatment group underwent tuberculosis screening by means of the Xpert MTB/RIF test, urinary lipoarabinomannan test, and chest radiography to determine whether treatment for tuberculosis should be implemented, and the patients assigned to the systematic-treatment group received empirical treatment for tuberculosis with the World Health Organization–recommended regimen of rifampin, isoniazid, ethambutol, and pyrazinamide daily for 2 months, followed by rifampin and isoniazid daily for 4 months. ALT denotes alanine aminotransferase, ART antiretroviral therapy, AST aspartate aminotransferase, and ULN upper limit of the normal range.

events per 100 patient-years) was 19.4 in the systematic-treatment group and 20.3 in the guided-treatment group at week 24 (adjusted hazard ratio, 0.95; 95% confidence interval [CI], 0.63 to 1.44) (Table 2 and Fig. 2). The most common causes of death were tuberculosis (17 patients in the guided-treatment group and 4 in the systematic-treatment group), invasive bacterial disease (3 patients and 6 patients, respectively), and AIDS-defining illnesses (7 patients in each group). Six deaths in the guided-treatment group and 15 deaths in the systematic-

treatment group were of unknown cause (Table S19).

Overall, tuberculosis occurred in 117 patients (99 patients in the guided-treatment group and 18 patients in the systematic-treatment group), but this total includes 50 prevalent cases of tuberculosis that were diagnosed at baseline (49 cases in the guided-treatment group, including 3 cases of rifampin-resistant tuberculosis, according to Xpert MTB/RIF testing) and 67 cases of incident tuberculosis (50 cases in the guided-treatment group and 17 cases in the systematic-

Table 1. Characteristics of the Patients at Baseline and during Follow-up.*		
Characteristic	Guided Treatment (N = 525)	Systematic Treatment (N = 522)
Baseline		
Female sex — no. (%)	221 (42.0)	215 (41.2)
Median age (IQR) — yr	35 (29–41)	35 (29–41)
Median body-mass index (IQR) †	19.6 (17.9–21.9)	19.7 (17.8–21.9)
Karnofsky performance-status score — no. (%) ‡		
<80	27 (5.1)	27 (5.2)
≥80	497 (94.7)	494 (94.6)
Missing data	1 (0.2)	1 (0.2)
WHO clinical stage — no. (%)		
Stage 1	152 (29.0)	146 (28.0)
Stage 2	132 (25.1)	148 (28.4)
Stage >2	240 (45.7)	227 (43.5)
Missing data	1 (0.2)	1 (0.2)
Median CD4+ T-cell count (IQR) — cells/mm ³	28 (12–56)	32 (13–55)
CD4+ T-cell count — no. (%)		
≤50/mm ³	370 (70.5)	370 (70.9)
51–99/mm ³	155 (29.5)	152 (29.1)
Median plasma HIV-1 RNA level (IQR) — log ₁₀ copies/ml	5.5 (5.2–5.8)	5.4 (5.1–5.8)
Median hemoglobin level — g/dl	11.5 (9.9–13.4)	11.7 (9.9–13.2)
Positive plasma HBV surface antigen — no. (%)	47 (9.0)	48 (9.2)
Positive plasma HCV antibodies — no. (%)	36 (6.9)	35 (6.7)
Plasma ALT >2.5× ULN — no. (%)	49 (9.3)	36 (6.9)
Patients with tuberculosis symptoms according to WHO criteria — no. (%) §		
No symptoms	199 (37.9)	196 (37.5)
1 Symptom	155 (29.5)	150 (28.7)
2 Symptoms	90 (17.1)	103 (19.7)
3 Symptoms	62 (11.8)	58 (11.1)
4 Symptoms	18 (3.4)	15 (2.9)
Missing data	1 (0.2)	0
Follow-up		
Lost to follow-up — no. (%)	11 (2.1)	13 (2.5)
Follow-up time — person-yr	444	442
Initiated ART — no. (%)	523 (99.6)	510 (97.7)
First-line regimen		
Tenofovir + lamivudine or emtricitabine + efavirenz	490 (93.7)	473 (92.7)
Zidovudine + lamivudine + efavirenz	32 (6.1)	35 (6.9)
Other ¶	1 (0.2)	2 (0.4)
Medication possession ratio >95%	445 (85.1)	434 (85.1)
Initiated treatment for tuberculosis — no. (%)	93 (17.7)	521 (99.8)
Completed 6 mo of treatment	85 (91.4)	497 (95.4)

Table 1. (Continued.)

Characteristic	Guided Treatment (N = 525)	Systematic Treatment (N = 522)
Chest radiography performed — no. of patients/no. of tests		
At day 0	519/519	514/516
After day 0 and before wk 24	192/313	488/870
After wk 24	81/108	156/180
Urinary LAM test performed — no. of patients/no. of tests		
At day 0	524/524	1/1
After day 0 and before wk 24	146/183	24/26
After wk 24	43/54	14/17
Xpert MTB/RIF test performed on sputum sample — no. of patients/no. of tests		
At day 0	472/475	0/0
After day 0 and before wk 24	154/227	37/49
After wk 24	51/70	19/30

* None of the baseline characteristics differed significantly between strategies. Percentages may not total 100 because of rounding. ALT denotes alanine aminotransferase, ART antiretroviral therapy, HBV hepatitis B virus, HCV hepatitis C virus, HIV human immunodeficiency virus, IQR interquartile range, LAM lipoarabinomannan, ULN upper limit of the normal range, and WHO World Health Organization.

† The body-mass index is the weight in kilograms divided by the square of the height in meters.

‡ Karnofsky performance-status scores range from 0 to 100, with lower scores indicating greater disability.

§ Tuberculosis symptoms according to the WHO criteria⁵ include cough, fever, weight loss, and night sweats.

¶ All 3 patients received tenofovir, lamivudine, and lopinavir–ritonavir.

|| The medication possession ratio is the number of daily doses of antiretroviral drugs dispensed by the pharmacy to each patient, divided by that patient's total follow-up time in days since the initiation of ART.

treatment group). Among the 199 patients (37.9%) in the guided-treatment group who reported no tuberculosis symptoms at baseline, 10 (5.0%) received a diagnosis of prevalent tuberculosis. In the guided-treatment group, 29 cases of incident tuberculosis occurred before week 4, 9 cases between week 4 and week 8, 1 case between week 8 and week 12, 5 cases between week 12 and week 24, and 6 cases between week 24 and week 48. The 1 case of prevalent tuberculosis in the systematic-treatment group was documented according to a positive urinary LAM test that was incorrectly performed at enrollment. The 17 cases of incident tuberculosis in the systematic-treatment group included 11 cases of paradoxical tuberculosis-associated IRIS that occurred 3 to 70 days after the initiation of ART, 3 cases of tuberculosis that were diagnosed before week 24 (including 1 that occurred before the initiation of ART and 2 that occurred after an untimely discontinuation of treatment for tuberculosis 2 months after enrollment), and 3 cases that were diagnosed after week 24. All strains of

M. tuberculosis that were isolated in the systematic-treatment group were fully susceptible to anti-tuberculosis drugs. The cumulative probability of receiving a diagnosis of incident or prevalent tuberculosis was 3.0% in the systematic-treatment group and 17.9% in the guided-treatment group at week 24 (adjusted hazard ratio, 0.15; 95% CI, 0.09 to 0.26) and 3.6% and 19.2%, respectively, at week 48 (adjusted hazard ratio, 0.17; 95% CI, 0.10 to 0.28).

ART, VIROLOGIC RESPONSE, AND IMMUNE RECONSTITUTION

In the guided-treatment group, ART was initiated in 523 patients (99.6%): 477 (91.2%) started ART during the first week of the trial, and 40 (7.6%) started ART during the second week. In the systematic-treatment group, ART was initiated in 510 patients (97.7%): 447 (87.6%) started ART at week 2, and 32 (6.3%) started ART between week 2 and week 4. The ART medication possession ratio did not differ significantly between the two treatment groups (Table 1). The

Table 2. Clinical End Points at 24 and 48 Weeks.*

Clinical End Points	Guided Treatment		Systematic Treatment		Adjusted Hazard Ratio (95% CI)†‡
	No. of First Events	Rate (95% CI)‡	No. of First Events	Rate (95% CI)‡	
Primary end point at 24 wk: composite of death from any cause or invasive bacterial disease	46	20.3 (14.5–26.2)	44	19.4 (13.7–25.1)	0.95 (0.63–1.44)§
Secondary end points at 24 wk¶					
Death from any cause	36	15.6 (10.5–20.8)	33	14.4 (9.5–19.3)	0.92 (0.57–1.47)
Invasive bacterial disease	15	6.7 (3.7–11.0)	18	8.0 (4.7–12.6)	1.19 (0.60–2.36)
Tuberculosis	93	47.2 (37.6–56.8)	15	6.7 (3.7–11.0)	0.15 (0.09–0.26)
IRIS	57	26.8 (19.8–33.7)	17	7.6 (4.4–12.1)	0.39 (0.22–0.69)
AIDS-defining events	62	29.3 (22.0–36.5)	46	21.3 (15.1–27.5)	0.73 (0.50–1.06)
Grade 3 or 4 adverse events**	125	65.5 (54.0–76.9)	166	94.3 (80.0–108.7)	1.39 (1.11–1.76)
Grade 3 or 4 drug-related adverse events**	37	16.9 (11.5–22.3)	89	44.7 (35.4–54.0)	2.57 (1.75–3.78)
Secondary end points at 48 wk¶					
Composite of death from any cause or invasive bacterial disease	58	13.3 (9.9–16.7)	56	12.8 (9.5–16.2)	0.97 (0.67–1.40)
Death from any cause	45	10.1 (7.4–13.5)	45	10.2 (7.4–13.6)	1.01 (0.67–1.52)
Invasive bacterial disease	19	4.4 (2.7–6.9)	22	5.1 (3.2–7.7)	1.15 (0.62–2.13)
Tuberculosis	99	26.2 (21.0–31.3)	18	4.2 (2.5–6.6)	0.17 (0.10–0.28)
IRIS	59	14.4 (10.7–18.1)	17	3.9 (2.3–6.3)	0.27 (0.16–0.47)
AIDS-defining events	72	17.7 (13.6–21.8)	52	12.6 (9.2–16.0)	0.71 (0.49–1.01)
Grade 3 or 4 adverse events**	143	39.8 (33.3–46.4)	179	54.7 (46.7–62.8)	1.32 (1.06–1.65)
Grade 3 or 4 drug-related adverse events**	39	9.3 (6.4–12.2)	94	24.9 (19.9–30.0)	2.59 (1.78–3.76)

* AIDS denotes acquired immunodeficiency syndrome, and IRIS immune reconstitution inflammatory syndrome.

† The hazard ratios are for the systematic-treatment group as compared with the guided-treatment group and were adjusted for country (Ivory Coast, Uganda, Cambodia, or Vietnam) and baseline CD4+ T-cell count (≤ 50 per cubic millimeter or 51 to 99 per cubic millimeter).

‡ Rate was calculated as the number of first events per 100 patient-years.

§ $P=0.82$.

¶ Because the trial protocol did not include a plan for adjustment for multiple comparisons, the results of the analyses of secondary end points are reported with point estimates and 95% confidence intervals, without P values, and the results cannot be used to infer effects.

|| The end point of tuberculosis includes prevalent and incident cases. Of the 117 cases of tuberculosis, 54 included pulmonary involvement only, 18 included pulmonary and extra pulmonary involvement, and 45 included extrapulmonary involvement only.

** Adverse events were graded according to the criteria of the Division of AIDS.²³

HIV viral load was below 50 copies per milliliter in 576 of the 935 patients (61.6%) with available data on viral load at week 24 (298 of 466 patients [63.9%] in the guided-treatment group and 278 of 469 patients [59.3%] in the systematic-treatment group) and in 646 of the 885 patients (73.0%) with available data on viral load at week 48 (324 of 446 patients [72.6%] in the guided-treatment group and 322 of 439 patients [73.3%] in the systematic-treatment group). The median gain in the CD4+ T-cell count was 94 cells per cubic millimeter (interquartile range, 51 to 147)

Figure 2 (facing page). Kaplan–Meier Analysis of the Primary Composite End Point and End-Point Components.

Shown are the Kaplan–Meier curves for the probability of the primary composite end point of death from any cause or invasive bacterial disease (Panel A) and the probability of the end-point components of death from any cause (Panel B) and invasive bacterial disease (defined as a bacteremia or clinical, biologic, or radiologic signs compatible with a bacterial infection of any solid organ or sterile space). In each panel, the inset shows the same data on an enlarged y axis. I bars represent 95% confidence intervals.




Table 3. Distribution of Serious Adverse Events According to Treatment Group.

Serious Adverse Event	All Events (495 Events)*		Drug-Related Events (150 Events)†	
	Guided Treatment	Systematic Treatment	Guided Treatment	Systematic Treatment
	<i>number of events</i>			
Invasive bacterial infections	20	22	—	—
Isolated bacteremia	4	9	—	—
Bacterial pneumonia	8	4	—	—
Severe sepsis	2	4	—	—
Pyelonephritis	4	1	—	—
Necrotizing fasciitis	2	0	—	—
Bacterial enteritis	0	1	—	—
Salpingitis	0	1	—	—
Skin abscess	0	1	—	—
Appendicitis	0	1	—	—
Incident tuberculosis‡	50	17	—	—
Other AIDS-defining illnesses	31	39	—	—
Cryptococcosis	6	10	—	—
Nontuberculous mycobacteriosis	5	2	—	—
Pneumocystis pneumonia	5	6	—	—
Esophageal candidiasis	3	8	—	—
Cytomegalovirus retinitis	2	1	—	—
Isosporiasis	2	2	—	—
Cryptosporidiosis	1	3	—	—
Microsporidiosis	1	0	—	—
Progressive multifocal leukoencephalopathy	1	1	—	—
Kaposi's sarcoma	1	1	—	—
Solid tumors other than Kaposi's sarcoma	1	1	—	—
Wasting syndrome	3	4	—	—
Other grade 3 or 4 adverse events	119	197	45	105
Noninfectious transaminitis	26	43	17	39
Pruritus, rash, mucous ulcerations	8	35	8	34
Stevens–Johnson syndrome	2	3	2	3
Neutropenia	16	17	5	10
Anemia	7	14	1	4
Thrombopenia	0	3	0	1
Bicytopenia or pancytopenia	6	3	2	1
Neuropsychiatric disorders	5	6	4	3
Nonspecific acute fever	5	13	0	1
Nonspecific kidney failure	7	5	5	4
Vomiting	0	2	0	2
Hyperuricemia	0	1	0	1
Gynecomastia	1	2	1	2

Table 3. (Continued.)

Serious Adverse Event	All Events (495 Events)*		Drug-Related Events (150 Events)†	
	Guided Treatment	Systematic Treatment	Guided Treatment	Systematic Treatment
	<i>number of events</i>			
Other	36	50	0	0
Total	220	275	45	105

* During follow-up, 495 serious adverse events occurred in 322 patients. Serious adverse events were defined as invasive bacterial diseases, incident tuberculosis, other AIDS-defining diseases, and other grade 3 or 4 events (classified according to the Division of AIDS²³).

† The 150 serious drug-related adverse events are included with the 495 serious adverse events. Drug-relatedness was first assessed by an adjudication committee at the national level and was then reviewed by an international adjudication committee. The two committees were aware of the treatment-group assignments. A dash indicates that an event cannot be caused by medications.

‡ Overall, 117 patients had tuberculosis: 50 cases were diagnosed at baseline (prevalent tuberculosis) and 67 were diagnosed during follow-up as new cases (incident tuberculosis). Only the 67 incident cases are shown in this table.

at week 24 (105 cells per cubic millimeter in the guided-treatment group and 86 cells per cubic millimeter in the systematic-treatment group) and 140 cells per cubic millimeter (interquartile range, 91 to 207) at week 48 (147 cells per cubic millimeter and 133 cells per cubic millimeter in the two groups, respectively).

ADVERSE EVENTS

Overall, 495 serious adverse events (220 in the guided-treatment group and 275 in the systematic-treatment group) occurred in 322 patients (143 in the guided-treatment group and 179 in the systematic-treatment group), including 150 grade 3 or 4 drug-related adverse events (45 in the guided-treatment group and 105 in the systematic-treatment group) in 133 patients (39 in the guided-treatment group and 94 in the systematic-treatment group) (Table 3). The cumulative 24-week probability of grade 3 or 4 drug-related adverse events was 17.4% in the systematic-treatment group and 7.2% in the guided-treatment group (adjusted hazard ratio, 2.57; 95% CI, 1.75 to 3.78). Treatment for tuberculosis was stopped prematurely in 24 patients (4.6%) in the systematic-treatment group owing to adverse events. During follow-up, 79 cases of IRIS (59 in the guided-treatment group and 20 in the systematic-treatment group) occurred in 76 patients (59 in the guided-treatment group and 17 in the systematic-treatment group), including 60 cases of tuberculosis-associated IRIS (49 cases and 11 cases in the two groups, respectively).

DISCUSSION

The results of the STATIS trial showed that among severely immunosuppressed adults who had not previously received ART, systematic empirical treatment for tuberculosis was not superior to a strategy involving a combination of repeated tuberculosis screening and targeted treatment for tuberculosis. Both strategies were associated with a lower-than-expected rate of death or invasive bacterial disease at week 24, as compared with previous trials and studies. The initial systematic tuberculosis-screening strategy used at enrollment captured a high number of prevalent tuberculosis diagnoses among asymptomatic patients or those with few symptoms, and additional symptom-driven screening allowed early detection of incident tuberculosis after ART was initiated.

Empirical treatment for tuberculosis has accounted for up to 15% of instances in which treatment has been initiated in some health care settings.²⁰ Empirical treatment has been compared with isoniazid preventive therapy in one trial involving outpatients, which did not show a reduction in mortality at 6 months.²⁵ An open cluster-randomized trial also did not show a reduction in mortality or the risk of hospitalization at 6 months.²⁶ Another trial of empirical treatment for tuberculosis was stopped prematurely because of slow recruitment.²⁷ In the current trial, systematic treatment for tuberculosis was associated with a higher probability of grade

3 or 4 drug-related toxic effects than test-guided treatment, although treatment had to be stopped in only 4.6% of the patients in the systematic-treatment group because of adverse reactions. Although such drug-related toxic effects are nonfatal, they might lead physicians to avoid systematic treatment for tuberculosis if they have access to Xpert MTB/RIF and urinary LAM tests.

Our tuberculosis-screening strategy was used to detect prevalent tuberculosis, regardless of symptoms. At the time of screening, 5% of the asymptomatic patients received a diagnosis of tuberculosis. After the initiation of ART, in order to capture incident tuberculosis, these tests were repeated when the results of the WHO tuberculosis symptoms questionnaire⁵ were positive. This continuous strategy was a compromise between current practice and the repeated use of simple tests that are not yet routinely used in this context, although their usefulness in detecting tuberculosis in patients with advanced immunodeficiency has been shown.¹⁸ The use of this repeated-testing strategy identified 93 cases of tuberculosis in 525 patients (17.7%) at week 24, with the majority of patients receiving a diagnosis within the first 4 weeks — a rate similar to that in previous studies²⁸⁻³⁰ and probably reflecting the level of background tuberculosis in this population. In the population targeted by the trial, invasive bacterial diseases are important causes of death.³¹ When designing the composite primary end point, we speculated that 6 months of rifampin therapy could help to prevent some bacterial-associated illnesses. Although we cannot rule out a potential underestimation of invasive bacterial diseases in both treatment groups, our results suggest that treatment for tuberculosis did not have a detectable effect on the rate of invasive bacterial diseases.

This trial has several limitations. First, neither of the assigned strategies can be directly compared with those used in current practice. At the time the trial was designed, most clinicians used only sputum smear for tuberculosis screening before initiating ART, but we anticipated that the development of the Xpert MTB/RIF and urinary LAM tests would lead to their use in future care. Second, although isoniazid preven-

tive therapy was known to decrease the rate of, and mortality from, tuberculosis among HIV-infected adults living in areas with a high burden of tuberculosis,³² at the time of randomization, isoniazid preventive therapy was deliberately not given to the patients who were assigned to the guided-treatment group to avoid the potential risk of treating undiagnosed tuberculosis with isoniazid alone. Because the patients were regularly screened for tuberculosis at each trial visit, we considered that this strategy was acceptable during the 48 weeks of the trial. After completion of the trial, isoniazid preventive therapy was considered in accordance with the national tuberculosis policy at each trial site. Third, despite systematic review, causes of death remained undocumented in 21 patients (23%), particularly among the patients who died in the systematic-treatment group (15 of 45 patients). Unknown causes of death are common in such trials, even at trial sites that are familiar with clinical research involving patients who are coinfecting with tuberculosis and HIV.³³⁻³⁶

In conclusion, systematic empirical treatment for tuberculosis and treatment guided by specific testing had similar effects on the rate of death or invasive bacterial disease in a population of HIV-infected adults with CD4+ T-cell counts below 100 cells per cubic millimeter.

A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.

Supported by the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS, grant 12290).

No potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank the patients for their participation in the trial; the staff at the national tuberculosis and HIV/AIDS programs in Cambodia, Ivory Coast, Uganda, and Vietnam for their support and help in making this trial possible; Claire Rekaewicz, Nicolas Rouveau, Pauline Justumus, Noémie Mercier, Paula Garcia, and Alpha Diallo for their active support at the ANRS headquarters; Christine Danel for early discussions about the design of the trial; Allé Baba Dieng for his active role in implementing the trial; Andrew Ramsay, Célestin Mangoua, Laurence Weiss, and François Raffi (members of the trial scientific advisory board, chaired by Anthony D. Harries) for their important contributions to the trial; Philippe Flandre, Tom Harrison, Pierre-Marie Girard (members of the data and safety monitoring board, chaired by Peter Godfrey-Faussett) for their analysis of the trial progress and advice; and Jean-François Delfraissy for continuous support and helpful advice. This article is dedicated to the memory of Stephen D. Lawn, vice coinvestigator of the trial, whose work on tuberculosis–HIV coinfection still guides us to improve the care of severely immunosuppressed persons.

APPENDIX

The authors' full names and academic degrees are as follows: François-Xavier Blanc, M.D., Ph.D., Anani D. Badje, M.D., Ph.D., Maryline Bonnet, M.D., Ph.D., Delphine Gabillard, M.Sc., Eugène Messou, M.D., Conrad Muzoora, M.D., Sovannarith Samreth, M.D., Bang D. Nguyen, M.D., Laurence Borand, Pharm.D., Ph.D., Anaïs Domergue, M.Sc., Delphine Rapoud, Ph.D., Naome Natukunda, M.D., Sopheak Thai, M.D., Sylvain Juchet, Pharm.D., Serge P. Eholié, M.D., Ph.D., Stephen D. Lawn, M.D., Ph.D., Serge K. Domoua, M.D., Xavier Anglaret, M.D., Ph.D., and Didier Laureillard, M.D.

The authors' affiliations are as follows: the Department of Respiratory Medicine, L'Institut du Thorax, Nantes University Hospital, and the Medical School, University of Nantes, Nantes (F.-X.B.), INSERM Unité 1219, University of Bordeaux, Bordeaux (A.D.B., D.G., X.A.), Relations Translationnelles sur le VIH et les Maladies Infectieuses, Institut de Recherche pour le Développement, University of Montpellier, INSERM (M.B.), and Research Unit 1058 Pathogenesis and Control Chronical Infections, INSERM, French Blood Center, University of Montpellier (D.L.), Montpellier, and the Department of Infectious and Tropical Diseases, Nîmes University Hospital, Nîmes (D.L.) — all in France; Programme ANRS (Agence Nationale de Recherches sur le Sida et les Hépatites Virales) Coopération Côte d'Ivoire, ANRS research site (A.D.B., E.M., S.J.), and Félix Houphouët-Boigny University (S.P.E., S.K.D.) — both in Abidjan, Ivory Coast; Epicentre (M.B., N.N.) and Mbarara University of Science and Technology (C.M.) — both in Mbarara, Uganda; the National Center for HIV/AIDS, Dermatology, and Sexually Transmitted Diseases (S.S.), Institut Pasteur du Cambodge (L.B.), and Sihanouk Hospital Center of Hope (S.T.) — all in Phnom Penh, Cambodia; Pham Ngoc Thach Hospital (B.D.N.) and ANRS, Pham Ngoc Thach Hospital (A.D., D.R.), Ho Chi Minh City, Vietnam; and the Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London (S.D.L.).

REFERENCES

1. Global tuberculosis report 2019. Geneva: World Health Organization, 2019.
2. Chrétien J. Tuberculosis and HIV: the cursed duet. *Bull Int Union Tuberc Lung Dis* 1990;65:25-8.
3. GBD Tuberculosis Collaborators. Global, regional, and national burden of tuberculosis, 1990-2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study. *Lancet Infect Dis* 2018;18:1329-49.
4. Gupta A, Nadkarni G, Yang W-T, et al. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. *PLoS One* 2011;6(12):e28691.
5. Guidelines for intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource constrained settings. Geneva: World Health Organization, 2010.
6. Systematic screening for active tuberculosis: principles and recommendations. Geneva: World Health Organization, 2013.
7. Chamie G, Luetkemeyer A, Walusimbi-Nanteza M, et al. Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata. *Int J Tuberc Lung Dis* 2010;14:1295-302.
8. Avila D, Althoff KN, Mugglin C, et al. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. *J Acquir Immune Defic Syndr* 2014;65(1):e8-e16.
9. Gesesew HA, Ward P, Woldemichael K, Mwanri L. Late presentation for HIV care in Southwest Ethiopia in 2003-2015: prevalence, trend, outcomes and risk factors. *BMC Infect Dis* 2018;18:59.
10. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. *AIDS* 2008;22:1897-908.
11. Moore DM, Yiannoutsos CT, Musick BS, et al. Determinants of early and late mortality among HIV-infected individuals receiving home-based antiretroviral therapy in rural Uganda. *J Acquir Immune Defic Syndr* 2011;58:289-96.
12. Kouanda S, Meda IB, Nikiema L, et al. Determinants and causes of mortality in HIV-infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective cohort study. *AIDS Care* 2012;24:478-90.
13. Marcy O, Laureillard D, Madec Y, et al. Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial. *Clin Infect Dis* 2014;59:435-45.
14. Odone A, Amadasi S, White RG, Cohen T, Grant AD, Houben RMGJ. The impact of antiretroviral therapy on mortality in HIV positive people during tuberculosis treatment: a systematic review and meta-analysis. *PLoS One* 2014; 9(11):e112017.
15. Ford N, Shubber Z, Meintjes G, et al. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. *Lancet HIV* 2015;2(10):e438-e444.
16. Ford N, Matteelli A, Shubber Z, et al. TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis. *J Int AIDS Soc* 2016; 19:20714.
17. Janssen S, Schutz C, Ward AM, et al. Hemostatic changes associated with increased mortality rates in hospitalized patients with HIV-associated tuberculosis: a prospective cohort study. *J Infect Dis* 2017;215:247-58.
18. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. *Lancet Infect Dis* 2012;12:201-9.
19. Lawn SD, Ayles H, Egwaga S, et al. Potential utility of empirical tuberculosis treatment for HIV-infected patients with advanced immunodeficiency in high TB-HIV burden settings. *Int J Tuberc Lung Dis* 2011;15:287-95.
20. McCarthy K, Fielding K, Churchyard GJ, Grant AD. Empiric tuberculosis treatment in South African primary health care facilities — for whom, where, when and why: implications for the development of tuberculosis diagnostic tests. *PLoS One* 2018;13(1):e0191608.
21. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA* 2013;310:2191-4.
22. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: ICH harmonised tripartite guideline. Guideline for good clinical practice E6 (R1). 2002 (https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e6-r1-guideline-good-clinical-practice_en.pdf).
23. National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, corrected version 2.1. July 2017 (<https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf>).
24. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. *Lancet Infect Dis* 2008;8:516-23.

25. Hosseinipour MC, Bisson GP, Miyahara S, et al. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. *Lancet* 2016;387:1198-209.
26. Grant AD, Charalambous S, Tlali M, et al. Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial. *Lancet HIV* 2020;7(1):e27-e37.
27. Manabe YC, Worodria W, van Leth F, et al. Prevention of early mortality by presumptive tuberculosis therapy study: an open label, randomized controlled trial. *Am J Trop Med Hyg* 2016;95:1265-71.
28. Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker L-G, Wood R. Urine lipooligosaccharide assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. *AIDS* 2009;23:1875-80.
29. Bassett IV, Wang B, Chetty S, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. *Clin Infect Dis* 2010;51:823-9.
30. Lawn SD, Brooks SV, Kranzer K, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. *PLoS Med* 2011;8(7):e1001067.
31. Karat AS, Omar T, von Gottberg A, et al. Autopsy prevalence of tuberculosis and other potentially treatable infections among adults with advanced HIV enrolled in out-patient care in South Africa. *PLoS One* 2016;11(11):e0166158.
32. Badje A, Moh R, Gabillard D, et al. Effect of isoniazid preventive therapy on risk of death in West African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. *Lancet Glob Health* 2017;5(11):e1080-e1089.
33. Blanc F-X, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. *N Engl J Med* 2011;365:1471-81.
34. Lan NTN, Thu NTN, Barrail-Tran A, et al. Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam. *PLoS One* 2014;9(1):e84866.
35. Jindani A, Borgulya G, de Patiño IW, et al. A randomised phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis. *Int J Tuberc Lung Dis* 2016;20:832-8.
36. The TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. *N Engl J Med* 2015;373:808-22.

Copyright © 2020 Massachusetts Medical Society.

TRACK THIS ARTICLE'S IMPACT AND REACH

Visit the article page at [NEJM.org](https://www.nejm.org) and click on Metrics for a dashboard that logs views, citations, media references, and commentary. [NEJM.org/about-nejm/article-metrics](https://www.nejm.org/about-nejm/article-metrics).